phase IIa

Related by string. Phase IIa * phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical / IIA . IIAS : Phase IIa clinical trials . IIa clinical trial * Phase IIa Clinical Trial . Phase IIa trial . initiate Phase IIa . Phase IIa clinical . phase IIa clinical . Phase IIa trials . Phase IIa proof . exploratory Phase IIa . Phase IIa Trial . Phase IIa Evidence *

Related by context. All words. (Click for frequent words.) 84 phase IIa clinical 83 phase IIb 81 Phase Ib clinical 80 phase IIb clinical 79 Phase IIIb clinical 79 Phase Ib 79 Phase 1b clinical 79 Phase IIa 79 Phase IIa trial 78 phase Ib 78 Phase III 78 Phase IIa clinical 78 Phase 2b study 78 Phase IIb 78 Phase 2a clinical 78 phase 2a 77 Phase #b/#a 77 Phase 2a 77 Phase 1a clinical 77 Phase 2a trial 77 Phase III clinical 77 Phase Ia 77 multicenter Phase II 76 Phase IIb clinical 76 Phase IIb trial 76 Phase Ib study 76 phase IIb study 76 phase Ib clinical 76 Phase IIB 76 Phase 2b clinical 75 phase IIb trial 75 randomized Phase IIb 75 Phase III trials 75 dose escalation clinical 75 Phase 2b 75 Phase Ib II 75 Phase IIb trials 75 Phase #/#a 74 Phase 2b trial 74 Phase IIa trials 74 BRIM3 74 Phase 1a 74 multicenter phase 74 multicenter Phase 74 Phase 1b 74 Phase 1b trial 74 Phase 2b clinical trials 74 confirmatory Phase III 74 dose escalation Phase 73 placebo controlled Phase III 73 Phase II 73 pivotal Phase III 73 ADVANCE PD 73 pivotal bioequivalence 73 phase IIIb 73 APEX PD 73 Phase Ib IIa 72 placebo controlled Phase 72 Phase IIIb 72 Phase IIb clinical trials 72 clinical trial 72 INCB# [001] 72 pharmacokinetic PK study 72 placebo controlled clinical 72 TMC# C# 72 riociguat 71 Phase III psoriasis 71 NO# [002] 71 JAK inhibitor 71 cannabinor 71 Phase III randomized controlled 71 multicenter Phase III 71 Phase #b/#a clinical 71 alvespimycin 71 IIa trial 71 RSD# oral 71 Phase 2a clinical trials 71 GALNS 71 double blinded randomized 71 multicenter randomized placebo controlled 71 phase IIb III 70 CUSTOM III 70 registrational 70 blinded randomized placebo controlled 70 randomized Phase III 70 midstage trials 70 Corlux 70 multicenter randomized Phase 70 Phase IIb III 70 PFO migraine 70 Initiate Phase 70 ABSORB trial 70 axitinib 70 randomized controlled Phase 70 Zenvia Phase III 70 Phase III confirmatory 70 Phase III pivotal 70 Phase IIIb study 70 elotuzumab 70 multicenter clinical 70 initiate Phase 2b 70 BRIM2 70 MEND CABG 70 LUMINATE 70 multiple ascending dose 70 multicentre randomized 70 oral ridaforolimus 70 randomized Phase 2b 70 Fx #A 70 confirmatory clinical 69 GAMMAGARD 69 initiate Phase IIb 69 Phase 1b clinical trials 69 LUX Lung 69 HuMax EGFr 69 KRN# 69 IMA# 69 Phase Ib clinical trials 69 Phase 2b kidney transplant 69 ocrelizumab 69 TEMSO 69 dose escalation trial 69 Pivotal Phase III 69 QLT# 69 NP2 Enkephalin 69 Phase IIa proof 69 Phase III Clinical Trial 69 CRLX# 69 TBC# 69 Oglemilast 69 lomitapide 69 IIa clinical 69 Cloretazine ® 69 GetGoal Phase III 69 IIa clinical trial 69 Phase III placebo controlled 69 ENDEAVOR IV 69 Phase III clinical trials 69 TG MV 69 Pivotal Trial 68 thorough QT 68 ELACYT 68 RhuDex 68 teriflunomide 68 Phase #b/#a trial 68 ToGA 68 AVADO 68 confirmatory Phase 3 68 HCV SPRINT 68 GLP toxicology studies 68 OvaRex ® MAb 68 velafermin 68 budesonide foam 68 Plicera 68 brivaracetam 68 PRIMO CABG 68 mertansine 68 aclidinium bromide 68 EchoCRT 68 rALLy clinical trial 68 Dacogen injection 68 IIb clinical trial 68 Onrigin 68 EndoTAG TM -1 68 ORMD 68 photoprotective drug 68 R#/MEM # 68 placebo controlled randomized 68 ongoing Phase 1b 68 tolevamer 68 fostamatinib 68 TOLAMBA 68 PEARL SC 68 double blinded placebo 68 clinical pharmacology studies 68 fosbretabulin 68 MIST II 68 Aryplase 68 initiate Phase 1b 68 SUCCEED trial 68 CEQ# 68 IIa trials 68 evaluating tivozanib 68 Aflibercept 68 randomized multicenter 68 dirucotide 68 receptor tyrosine kinase inhibitor 68 CHAMPION PCI 68 dosing cohort 68 viral kinetic 68 huC# DM4 68 elacytarabine 68 initiated Phase Ib 68 multicenter randomized controlled 68 FOLOTYN ® 68 MERLIN TIMI 68 Mipomersen 67 oral methylnaltrexone 67 clinical trials 67 prospective multicenter randomized 67 Phase 2a proof 67 multicenter prospective 67 Initiated Phase 67 AIR CF1 67 randomized multicenter trial 67 omacetaxine mepesuccinate 67 Phase IIa clinical trials 67 HGS# 67 trastuzumab DM1 T DM1 67 RhuDex ® 67 TASKi2 67 HCV RESPOND 2 67 CLARITY study 67 prospective randomized multicenter 67 Alzhemed TM 67 randomized controlled multicenter 67 rALLy trial 67 forodesine 67 PF # [002] 67 multicenter placebo controlled 67 Phase IIb Trial 67 pharmacokinetic PK 67 Zenvia ™ 67 ANCHOR trial 67 ILLUMINATE 67 PANVAC VF 67 Androxal TM 67 GSK# [002] 67 Cloretazine R VNP#M 67 Allovectin 7 67 PDE4 inhibitor 67 TASKi3 67 Quinamed 67 preclinical efficacy 67 Cloretazine 67 TMC# [002] 67 registrational trial 67 Randomized Phase 67 Safinamide 67 OncoVEX GM CSF 67 Multiple Ascending Dose 67 Archexin 67 vidofludimus 67 bicifadine 67 Intervention Effectiveness 67 single ascending dose 67 dosing cohorts 67 GOUT 67 efficacy endpoint 67 Aplidin 67 oral prodrug 67 AIR CF2 67 ENDEAVOR III 67 acyclovir Lauriad R 67 tanespimycin 67 AZILECT ® 67 SPIRIT FIRST 67 Pivotal Study 67 UPLYSO 67 TACI Ig 67 Phase IIA 67 BLA filing 67 CAMMS# 67 MAGE A3 ASCI 67 VNP#M 67 IMPACT IMmunotherapy 67 Phenoptin 67 CRMD# 67 ADAGIO study 67 afamelanotide 67 placebo controlled 67 virus HCV protease inhibitor 67 HuMax CD4 67 PRX # 66 dose escalation phase 66 mGluR5 NAM 66 ganetespib 66 lumiliximab 66 reslizumab 66 Prostate AdenoCarcinoma Treatment 66 II Clinical Trial 66 EGS# 66 dose escalation study 66 randomized blinded 66 histone deacetylase HDAC inhibitor 66 baminercept 66 Sapacitabine 66 LCP AtorFen 66 investigational protease inhibitor 66 BCX# 66 Urocidin 66 blinded randomized 66 midstage clinical 66 randomized multicenter Phase III 66 YONDELIS 66 Elagolix 66 Lu AA# 66 Phase III Clinical Trials 66 pivotal Phase 66 Proellex TM 66 CBLC# 66 ORAL Sync 66 fidaxomicin Phase 3 66 DermaVir Patch 66 Traficet EN 66 antibody MAb 66 Phase III registrational 66 bardoxolone 66 DASISION 66 interferon beta 1b 66 neratinib 66 Daclizumab 66 SNT MC# 66 dyskinesia PD LID 66 Amrubicin 66 Phase III Pivotal 66 Pivotal Phase 66 dose cohort 66 diabetic neuropathic pain 66 AeroLEF TM 66 EXPLORE Xa 66 blinded placebo controlled 66 prospective multicenter 66 Ozarelix 66 ATL# [001] 66 NVA# 66 Diamyd ® 66 SAR# [004] 66 trastuzumab emtansine T DM1 66 PSN# [002] 66 Cinquil 66 Desmoteplase 66 Sorafenib HCC Assessment 66 ABSORB clinical 66 Phase 2b Clinical Trial 66 pomalidomide 66 Ophena TM 66 OHR/AVR# 66 oral rivaroxaban 66 ACTEMRA TM 66 Bicifadine 66 TRO# 66 OLYMPIA registry 66 masked placebo controlled 66 OvaRex 66 STRIDE PD 66 NSABP C 66 Capesaris 66 canakinumab 66 CCR5 antagonist 66 ITAX 66 Ocrelizumab 66 Multicenter 66 REVIVE Diabetes 66 multicenter randomized clinical 66 phase III isavuconazole 66 prospective randomized controlled 66 randomized placebo controlled 66 AEGR 66 prospective randomized placebo 66 initiate Phase Ib 66 mg/m2 cohort 66 Aurexis 66 Tarceva TM 66 Phase III randomized 66 lintuzumab 66 BNC# 66 PSMA ADC 66 arzoxifene 65 compound INCB# 65 COMFORT II 65 trodusquemine 65 assessing T DM1 65 CLIRS trial 65 HQK 65 Relovair 65 safinamide 65 CDP# 65 dose escalation 65 stated Michelle Berrey 65 tramiprosate Alzhemed TM 65 IND enabling 65 PEG SN# 65 Phase III Trial 65 eosinophilic asthma 65 Pimavanserin 65 IMPACT DCM 65 AIM HIGH 65 LymphoStat B TM 65 selective androgen receptor modulator 65 vemurafenib 65 Zybrestat 65 pertuzumab 65 PRT# 65 RGB # 65 randomized multicentre 65 Annamycin 65 ProSavin 65 visilizumab 65 Phase III VISTA 65 Canvaxin 65 multicentre randomized double 65 ONCONASE R 65 randomized Phase 65 miconazole Lauriad ® 65 TLK# 65 Phase III multicenter 65 PD LID 65 BOLDER II 65 GLYX 65 ruxolitinib 65 EMPHASIS HF trial 65 teduglutide 65 ExTRACT TIMI 65 non nucleoside inhibitor 65 metastatic hormone refractory 65 SUTENT ® 65 volociximab 65 tezampanel NGX# 65 APEX AMI trial 65 HuMax CD# 65 KNS # 65 Lodotra TM 65 RRMS patients 65 generation purine nucleoside 65 DDP# 65 active comparator 65 Dasatinib 65 initiate Phase IIa 65 pharmacokinetics PK 65 relapsing remitting MS RRMS 65 Tocosol Paclitaxel 65 VA# [002] 65 severe hypercholesterolemia 65 aclidinium 65 prospective observational 65 GSK# [001] 65 satraplatin Phase 65 trastuzumab DM1 65 SCH # 65 GLPG# 65 cediranib 65 Valtropin 65 treatment naive genotype 65 TAXUS ATLAS 65 Phase 2b monotherapy 65 HGS ETR1 65 Alocrest 65 labial herpes 65 IL# PE#QQR 65 midstage studies 65 preclinical pharmacokinetic 65 LCP Tacro 65 refractory CLL 65 EVEREST II 65 Exherin TM 65 Sym# 65 multicenter multinational 65 relapsing multiple sclerosis 65 oral FTY# 65 cathepsin K inhibitor 65 Zemplar Capsules 65 Vicriviroc 65 olaparib 65 Combination REOLYSIN R 65 MIVI III 65 CLIRS 65 multicenter randomized 65 PEG IFN 65 CR# vcMMAE 65 MEND CABG II 65 PROSTVAC TM 65 PRESEPT 65 PXD# 65 dirucotide MBP# 65 metastatic castration resistant 65 REG2 65 randomized clinical 65 CLORETAZINE TM VNP#M 65 PRTX 65 Spiegelmer ® 64 TELINTRA 64 Phase III HEAT 64 eprotirome 64 Viramidine 64 multicenter randomized double 64 JAK2 inhibitor 64 PRE SURGE 64 pharmacokinetic studies 64 Tanespimycin 64 NLX P# 64 Phase 2a Clinical Trial 64 Darusentan 64 Phase #/#a clinical 64 glufosfamide 64 LAB CGRP 64 PEG PAL 64 clevidipine 64 Altastaph 64 Zenvia TM 64 rilonacept 64 ACTIVE W 64 CA9 SCAN 64 Tyrima 64 tremelimumab 64 Hsp# Inhibitor 64 Aclidinium 64 cariprazine 64 Vitaxin 64 unblind 64 Hepatitis C HCV 64 Prosaptide 64 sorafenib Nexavar 64 Onconase 64 Sprycel dasatinib 64 Phase 64 AVERROES 64 MAXY alpha 64 TRANSFORMS 64 LAF# 64 Microplasmin 64 AQ4N 64 clazosentan 64 IND submission 64 obatoclax 64 BCIRG 64 dextromethorphan quinidine 64 dose cohorts 64 oral treprostinil 64 Elocalcitol 64 Certolizumab pegol 64 enzastaurin 64 APPRAISE 64 ritonavir boosted danoprevir 64 XL# SAR# 64 ascending dose 64 Phase IIb kidney transplant 64 DU #b 64 VITAL Trial 64 phase III ACCLAIM 64 CARE HF 64 iniparib 64 PREOS 64 PERSEUS 64 Cimzia TM 64 Pirfenidone 64 EURIDIS 64 Panzem R NCD 64 ponatinib 64 Carfilzomib 64 Randomized Double blind 64 MAP# 64 DEB# 64 seliciclib CYC# 64 randomized controlled clinical 64 ONTARGET 64 NOX E# 64 AZILECT R 64 bortezomib Velcade 64 BAY #-# 64 lintuzumab SGN 64 SYMMETRY trial 64 Allovectin 7 R 64 Phase III ADT 64 label multicenter 64 pharmacodynamic PD 64 OncoVex 64 almorexant 64 dexanabinol 64 modified REGENESIS Phase IIb 64 rEV# 64 opioid induced bowel dysfunction 64 SinuNase TM 64 Feasibility Trial 64 refractory acute myeloid 64 albiglutide 64 LibiGel Phase III 64 PHX# 64 CB2 selective receptor agonist 64 Dalbavancin 64 ZYBRESTAT 64 BR.# 64 Forodesine HCl 64 Catena ® 64 deforolimus 64 novel VDA molecule 64 RECORD1 64 Anturol TM 64 inhibitor RG# 64 Temsirolimus 64 Trofex 64 Enobia 64 CIMZIA TM certolizumab pegol 64 EVIZON TM 64 nonrandomized 64 eltrombopag 64 Cannabinor 64 relapsed refractory multiple myeloma 64 OvaRex R 64 lorvotuzumab mertansine 64 multicentre 64 SCENESSE ® 64 Edge STudy 64 docetaxel Taxotere R 64 NSABP B 64 Omnitarg 64 torezolid phosphate 64 bendamustine 64 ganaxolone 64 huN# DM1 64 HGS ETR2 64 ancrod 64 treatment naïve genotype 64 placebo controlled clinical trials 64 PRECISE Trial 64 SPIRIT III 64 RE LY ® 64 crizotinib PF # 64 controlled multicenter Phase 64 CUSTOM II 64 unblinding 64 Meets Primary Endpoint 64 galiximab 64 registrational Phase 64 MADIT II 64 dose dose escalation 64 recurrent glioblastoma multiforme 64 tezampanel 64 BETAS 64 mapatumumab 64 subcutaneously administered 64 Silodosin 64 Phase Ib IIa clinical 64 nucleotide analog 64 Denufosol 64 celgosivir 64 ZACTIMA 64 Nexavar sorafenib 64 AEG# 63 Glybera R 63 subanalysis 63 INSPIRE Trial Phase III 63 PRECISE 63 Phase lll 63 tocilizumab 63 vicriviroc 63 Clinical Trial Results 63 REMUNE R 63 DSMB recommended 63 Acute Ischemic Stroke 63 double blind placebo 63 ALN VSP Phase 63 ularitide 63 BrachySil TM 63 GV# [001] 63 Tesetaxel 63 BRAF inhibitor 63 Laquinimod 63 COPERNICUS 63 Rezular 63 AIMM trial 63 CATIE AD 63 Vernakalant 63 Kahalalide F 63 Phase #/#a trial 63 investigational humanized monoclonal antibody 63 PDX pralatrexate 63 Initiates Phase II 63 StemEx R 63 PREOS R 63 CALGB 63 evaluating Actimmune 63 Omacetaxine 63 Phase 1b dose escalation 63 hepatitis B vaccine Heplisav 63 alemtuzumab Campath 63 R#/MEM 63 Pivotal Clinical Trial 63 apricitabine 63 PEGylated interferon beta 1a 63 LBH# 63 Completes Patient Enrollment 63 eniluracil 63 CG# [003] 63 Allovectin 7 ® 63 ofatumumab HuMax CD# 63 RE LY 63 OMNARIS HFA 63 ORENCIA ® 63 ChronVac C ® 63 VIR# 63 prucalopride 63 inhaled AAT 63 PRIMO CABG2 63 Vilazodone 63 dimebon 63 ospemifene 63 desvenlafaxine succinate 63 ASCEND HF 63 resminostat 63 ATTRACT 63 Phase 2b randomized 63 IMC #B 63 ACCLAIM II 63 TELCYTA 63 ThermoDox R 63 cangrelor 63 CLL8 63 NV1FGF 63 MEK inhibitor 63 PrevOnco 63 ASA# 63 LymphoStat B 63 RhuDex TM 63 Balaglitazone 63 HCD# [002] 63 CALGB # [002] 63 mipomersen 63 balsalazide tablet 63 PRECISE trial 63 GRAVITAS trial 63 Fentanyl TAIFUN R 63 octreotide implant 63 Luveniq 63 preclinical 63 catheter occlusion 63 APTIVUS 63 NGX# 63 adecatumumab MT# 63 novel oral anticoagulant 63 Phase III metastatic melanoma 63 sunitinib malate 63 Fibrillex TM 63 nitazoxanide 63 ozarelix 63 Tarvacin TM 63 nucleotide analogue 63 cilengitide 63 cetuximab Erbitux 63 vascular disrupting agent 63 ICA # 63 PHASE III 63 Pegasys plus Copegus 63 Zoraxel 63 sitaxsentan 63 telaprevir dosing 63 IPL# 63 ACCEDE 63 ocular formulation 63 Golimumab 63 COSIRA trial 63 GRN# 63 Prodarsan ® 63 RSD# 63 ISIS # 63 MBP# [001] 63 interferon gamma 1b 63 liposomal formulation 63 MGd 63 Prodarsan 63 Fodosine 63 OncoVEX 63 controlled multicenter 63 glucokinase activator 63 Ereska 63 incyclinide 63 confirmatory Phase 63 refractory chronic lymphocytic 63 Arikace 63 senicapoc 63 Nuvion 63 viral kinetics 63 Asentar 63 Neupro R 63 Phase 2b Trial 63 Factor VIIa 63 GW# [003] 63 orally inhaled migraine 63 metaglidasen 63 Gattex 63 Ambrisentan 63 Lovaxin C 63 Vascular Disrupting Agent 63 CytoFabTM 63 maribavir 63 SNT-MC#/idebenone 63 recurrent herpes labialis 63 Hyphanox 63 refractory gout 63 ILUVIEN ® 63 MIRCERA 63 vosaroxin 63 Civacir 63 methylnaltrexone 63 EOquin TM 63 preclinically 63 Genz # 63 blind randomized placebo 63 alvimopan 63 Phase IIB clinical 63 Trovax 63 Phase IIb Clinical Trial 63 canagliflozin 63 Deforolimus 63 rNAPc2 63 daclizumab 63 Xanafide 63 BAL# [002] 63 VEGF Trap 63 Trandolapril 63 pharmacokinetic 63 QNEXA 63 RG# [001] 63 randomized blinded placebo 63 sapacitabine 63 Xelox 63 Epratuzumab 63 Romidepsin 63 midstage clinical trial 63 ORACLE MS 63 nalbuphine ER 63 subcutaneous formulation 63 aflibercept 63 Personalized Immunotherapy 63 Hedgehog antagonist 63 OPT CHF 63 RELOVAIR ™ 63 PF # [001] 63 AVE# 63 initiate Phase 63 ataluren 63 Aurora kinase inhibitor 63 ENRICH trial 63 Telatinib 63 Nasdaq PGNX today 63 investigational pan BCR 63 evaluating REVLIMID 63 TAXUS IV 63 ascending doses 63 multicenter 63 Dyloject TM 63 placebo controlled studies 63 laquinimod 63 EmbraceAC 63 ACOMPLIA R 63 BLOOM DM 63 By JENNIFER LEARN 63 Kynapid 63 AERAS-#/Crucell Ad# 63 AIR2 Trial 63 Thorough QT 63 Testosterone MDTS ® 63 candidates Dyloject TM 63 Phase III Psoriasis 63 davunetide intranasal AL 63 NEVO ™ 63 Enzastaurin 63 Bezielle 63 multicenter trials 63 atrasentan 63 adipiplon 62 ANTEGREN 62 SEPET TM 62 trial evaluating PRX# 62 neurogenic orthostatic hypotension 62 ulimorelin 62 Parkinson disease levodopa induced 62 tesmilifene 62 bosutinib 62 relapsed ALL 62 sunitinib Sutent 62 Cetrorelix 62 ENESTnd 62 Tocilizumab 62 Urocortin 2 62 ACAPODENE 62 randomized discontinuation trial 62 Pafuramidine 62 L BLP# 62 TASQ 62 metastatic malignant 62 HCV NS5B polymerase 62 Vectibix panitumumab 62 XIENCE V Stent System 62 CYT# potent vascular disrupting 62 aleglitazar 62 Afatinib 62 LymphoStat B belimumab 62 Cethromycin 62 Randomised 62 OncoGel 62 HPTN 62 TPI ASM8 62 Dextofisopam 62 TransMID 62 tasocitinib 62 Cogane 62 MYDICAR 62 EDEMA3 62 nab paclitaxel 62 CRx 62 Triolex 62 MyVax personalized immunotherapy 62 bevirimat Study 62 mGluR2 positive 62 dexpramipexole 62 relapsing remitting multiple sclerosis 62 placebo controlled trials 62 motesanib 62 Iloperidone 62 null responder HCV 62 Ostarine 62 PRECiSE 62 orBec 62 Medidur TM FA 62 Phase III TRIST 62 intranasal formulation 62 novel histone deacetylase 62 candidate CRLX# 62 pradefovir 62 diarrhea predominant irritable 62 PreCISe 62 randomized controlled 62 Cimzia ® certolizumab pegol 62 EDEMA3 trial 62 Myelodysplastic Syndrome MDS 62 Revlimid lenalidomide 62 Azedra 62 MYDICAR ® 62 Successfully Completes Phase 62 generation PNP inhibitor 62 stage IIIB 62 Memryte 62 CD# CEA 62 Randomized controlled 62 MKC# MKC# PP 62 evaluating mipomersen 62 TAXUS VI 62 ENDEAVOR II 62 CoFactor 62 MKC# MT 62 Phase 2a Study 62 initiated Phase 1b 62 Roflumilast 62 lorcaserin Phase 62 Dacogen decitabine 62 Ceflatonin 62 relapsed MM 62 FlutiformTM 62 oral deforolimus 62 confirmatory pivotal 62 Clinical Antipsychotic Trials 62 ROCKET AF 62 ZYBRESTAT fosbretabulin 62 BiTE R 62 RoACTEMRA 62 MINDSET 62 Reverset 62 PEGylated interferon 62 microplasmin 62 IMPACT DCM clinical 62 Randomized Phase II 62 Phase III Trials 62 RezularTM 62 PROSTVAC VF 62 European Sepsis Trial 62 CCX# B 62 tasimelteon 62 Tezampanel 62 samalizumab 62 LAS# [002] 62 TG# [003] 62 MVax R 62 ECASS 62 OMAPRO ™ 62 sNDA submission 62 Degarelix 62 IMGN# 62 Bronchitol 62 HDL Selective Delipidation 62 maximally tolerated dose 62 DXL# 62 subcutaneous PRO 62 ketolide antibiotic 62 Pazopanib 62 iclaprim 62 VFEND 62 denufosol 62 Solulin 62 CIMZIA TM 62 ATL/TV# 62 ZD# [001] 62 OXi# 62 LibiGel ® 62 Glybera 62 Tasimelteon 62 varespladib 62 faropenem 62 lixisenatide

Back to home page